The vaccine for this population is usually AREXVY. Receiving your vaccine doesn’t only help you, it helps the people around you stay healthy as well. “You know, I always say that an ounce of ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...